Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom.
Suet Ching ChenAntonia DastamaniDonatella PintusDaphne YauSommayya AftabLouise BathCraig SwinburneLindsey HunterAlessandro GiardiniGeorgi ChristovSenthil SenniappanIndraneel BanerjeeMohamad Guftar ShaikhPratik ShahPublished in: Clinical endocrinology (2019)
Pulmonary hypertension can occur in 7% of diazoxide-treated HH patients. Risk factors include the presence of congenital heart disease and fluid overload. Recommendations include echocardiography and fluid restriction to 130 mL/kg/d prior to diazoxide treatment and immediate discontinuation of diazoxide if PH develops.
Keyphrases
- pulmonary hypertension
- congenital heart disease
- risk factors
- end stage renal disease
- pulmonary artery
- pulmonary arterial hypertension
- chronic kidney disease
- ejection fraction
- type diabetes
- peritoneal dialysis
- left ventricular
- computed tomography
- prognostic factors
- diabetic rats
- high glucose
- cross sectional
- heart failure
- combination therapy
- stress induced